Follow
Sam Wilks
Sam Wilks
Verified email at cam.ac.uk
Title
Cited by
Cited by
Year
Antibody landscapes after influenza virus infection or vaccination
JM Fonville, SH Wilks, SL James, A Fox, M Ventresca, M Aban, L Xue, ...
Science 346 (6212), 996-1000, 2014
4322014
Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands
R Bodewes, G de Mutsert, FRM Van Der Klis, M Ventresca, S Wilks, ...
Clinical and Vaccine Immunology 18 (3), 469-476, 2011
1722011
Defining the risk of SARS-CoV-2 variants on immune protection
MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ...
Nature 605 (7911), 640-652, 2022
1332022
A review of influenza haemagglutinin receptor binding as it relates to pandemic properties
S Wilks, M de Graaf, DJ Smith, DF Burke
Vaccine 30 (29), 4369-4376, 2012
902012
Mapping SARS-CoV-2 antigenic relationships and serological responses
SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ...
Science 382 (6666), eadj0070, 2023
682023
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
B Ying, B Whitener, LA VanBlargan, AO Hassan, S Shrihari, CY Liang, ...
Science translational medicine 14 (630), eabm3302, 2021
662021
Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant
DL Gordon, D Sajkov, Y Honda-Okubo, SH Wilks, M Aban, IG Barr, ...
Vaccine 34 (33), 3780-3786, 2016
592016
BA. 2 and BA. 5 omicron differ immunologically from both BA. 1 omicron and pre-omicron variants
A Rössler, A Netzl, L Knabl, H Schäfer, SH Wilks, D Bante, ...
Nature communications 13 (1), 7701, 2022
502022
Antigenic maps of influenza A (H3N2) produced with human antisera obtained after primary infection
JM Fonville, PLA Fraaij, G de Mutsert, SH Wilks, R van Beek, ...
The Journal of infectious diseases 213 (1), 31-38, 2016
372016
SARS-CoV-2 variant vaccine boosters trial: preliminary analyses
AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ...
MedRxiv, 2022.07. 12.22277336, 2022
342022
Influenza virus infection history shapes antibody responses to influenza vaccination
M Auladell, HVM Phuong, LTQ Mai, YY Tseng, L Carolan, S Wilks, ...
Nature medicine 28 (2), 363-372, 2022
342022
Analysis of SARS-CoV-2 omicron neutralization data up to 2021-12-22
A Netzl, S Tureli, E LeGresley, B Mühlemann, SH Wilks, DJ Smith
BioRxiv, 2021.12. 31.474032, 2022
222022
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ...
Nature medicine 29 (9), 2334-2346, 2023
112023
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
A Rössler, A Netzl, L Knabl, D Bante, SH Wilks, W Borena, D Von Laer, ...
Nature Communications 14 (1), 5224, 2023
82023
Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant immunologic landscape (COVAIL) trial
A Branche, N Rouphael, D Diemert, A Falsey, C Losada, LR Baden, ...
Research Square, 2023
32023
Influenza virus infection history drives and shapes antibody responses to influenza vaccination
A Fox, M Auladell, H Phuong, MQ Le, YY Tseng, L Carolan, S Wilks, ...
12021
Visualisation and analysis of patterns in serological data using" antibody landscapes"
SH Wilks
12018
Antigenic maps of influenza A/H3N2 virus produced with human antisera obtained after primary infection
JM Fonville, PLA Fraaij, G de Mutsert, SH Wilks, R van Beek, ...
J Infect Dis, 2015
12015
Characterization of A/H7 influenza virus global antigenic diversity and key determinants in the hemagglutinin globular head mediating A/H7N9 antigenic evolution
A Kok, R Scheuer, TM Bestebroer, DF Burke, SH Wilks, MI Spronken, ...
Mbio 14 (5), e00488-23, 2023
2023
Mapping SARS-CoV-2 antigenic relationships and serological responses
D Smith, S Wilks, S Tureli, A Netzl, E Legresley
2023
The system can't perform the operation now. Try again later.
Articles 1–20